Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas

NCT00227669 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT00227669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00227669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2005
Completion date
August 31, 2012
Enrollment
90 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma